European HIV vaccine candidate to begin safety trials
BY Advocate.com Editors
August 15 2003 12:00 AM ET
A Phase I clinical trial of an experimental HIV vaccine developed in Europe will begin in Switzerland and London this month, Agence France-Presse reports. The vaccine was developed by EuroVacc 01, a consortium of scientists and physicians across Europe, as well as the pharmaceutical company Aventis. The vaccine, which uses bits of genetic material from HIV to induce an immune system response to invading HIV, will undergo safety tests in HIV-negative male and female volunteers at the University of Lausanne's Centre Hospitalier Universitaire Vaudois in Switzerland and St. Mary's Hospital in London. Additional human tests will follow to gauge the efficacy of the vaccine. The clinical trial will be the first human study of a EuroVacc vaccine candidate.
- The Top 175 Essential Films of All Time for LGBT Viewers
- Leslie Jordan Banishes Antigay Starbucks Patrons: 'Get Out of My House!'
- Living Trans, From Iran to New York City
- Op-ed: The Far-Reaching Consequences of Dating App Racism
- In the Galleries: Are We Different?
- WATCH: A Straight Wedding Morphs Into a Gay Proposal